genuine question about retatrutide that I am slightly embarrassed to ask
genuine question about retatrutide that I am slightly embarrassed to ask. Searched first, found three threads that contradict each other, hence the post. The thing that surprised me was how much of the discussion here is inference rather than measurement. Watched heart rate on a wearable across twelve weeks because…
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
The injection-site soreness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
The injection-site soreness profile felt different rather than worse.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.